Ann: Neuren provides update on Fragile X and INTREPID trials, page-9

OK some history.

The 260 patient trial is divided 30/30/200 with escalating doses. The trial is a ratio 2:1 2566lacebo.

The first 30 were reported done in May 2011. The second in Nov 2011. Both of these were "checkpoints" where it was determined safe to go to the higher dose rates. In my quick re-read I didn't spot any other points along the trial where there's a review but that may be a combination of bad memory and bad reading.

LG has made a few comments along the way- guarded, and not outlandish. He has commented that the blinded data seems to show the drug is safe and well tolerated. There have been low SAEs and there has been a low mortality rate. Recent history with ACL (and longer term history with NEU) shows that this is a good sign but in no way definitive.

Until the data is unblinded we no that there seems to be no bad news, but we don't know if there is good news.

It's a bit of a worry that things seem to have slowed up again: only 7 patients in the last few months, by the sound of it. That blows out the worst case quite a bit: final patients by end year, 3 months follow up, data out by Jun 2016.

Hopefully they won't be that slow.

FXS on track. So that's good.